Three Or More Ring Hetero Atoms In The Additional Hetero Ring Patents (Class 514/236.2)
-
Publication number: 20110104155Abstract: A method and means for delivery of drugs to the chorio-retina and the optic nerve head which comprises contacting the surface of the eye with an effective amount of drug for treatment of chorio-retina and optic nerve head and a physiologically acceptable adrenergic agent for enhancing delivery of the drug to these tissues in an ophtalmologically acceptable carrier, said adrenergic agent being selected from the group consisting of alpha adrenergic agonist agents, derivatives of the alpha adrenergic agonist agents, beta-blocking agents, derivatives of the beta-blocking agents and mixtures thereof.Type: ApplicationFiled: May 5, 2008Publication date: May 5, 2011Applicant: Raouf RekikInventor: Raouf Rekik
-
Publication number: 20110105460Abstract: [Problem] A compound, which can be used for preventing or treating diseases, in which 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) is concerned, in particular, diabetes, insulin resistance, dementia, schizophrenia and depression, is provided. [Means for Solution] It was found that a triazole derivative, in which one of the 3- and 5-positions of the triazole ring has (di)alkylmethyl or cycloalkyl, each of which is substituted with —O— (aryl or a heterocyclic group, each of which may be substituted, or lower alkylene-cycloalkyl), and the other thereof has aryl, a heterocyclic group or cycloalkyl, each of which may be substituted, or a pharmaceutically acceptable salt thereof exhibits potent 11?-HSD1 inhibitory action. From the above, the triazole derivative of the present invention can be used for preventing or treating diabetes, insulin resistance, dementia, schizophrenia and depression.Type: ApplicationFiled: July 2, 2009Publication date: May 5, 2011Applicant: ASTELLAS PHARMA INC.Inventors: Seiji Yoshimura, Noriyuki Kawano, Tomoaki Kawano, Daisuke Sasuga, Takanori Koike, Hideyuki Watanabe, Hiroki Fukudome, Nobuyuki Shiraishi, Ryosuke Munakata, Hiroaki Hoshii, Kayoko Mihara
-
Publication number: 20110098267Abstract: The invention relates to a topical composition and a method for treating psoriasis. The topical composition comprises one or more compound that inhibits the production of IL-12 and IL-23.Type: ApplicationFiled: February 6, 2009Publication date: April 28, 2011Applicant: Synta Pharmaceuticals CorporationInventors: Suresh R. Babu, Yumiko Wada, Jianhua Shen, Nhung Nguyen
-
Publication number: 20110092507Abstract: The present invention provides a process for preparing optically active timolol. The process comprises the following steps. Firstly, reacting 3-hydroxy-4-morpholino-1,2,5-thiadiazole with an optically active epichlorohydrin in the presence of a solvent system, which has a first volume and a catalyst optionally in the presence of a suitable base to obtain an optically active intermediate product. Secondly, treating the optically active intermediate product with a solution, which has a second volume and comprises tert-butylamine to obtain an optically active timolol. The solvent system used in the first step can be an amide solvent, sulfoxide solvent, cyclic hydrocarbon solvent, ketone solvent, or a heterocyclic solvent. The catalyst used in the first step can be an alkali metal hydroxide, alkali metal carbonate, alkali metal hydrogen carbonate, piperidine, pyridine, triethylamine, potassium hydroxide, sodium hydroxide, potassium carbonate, and other heterocyclic bases.Type: ApplicationFiled: October 20, 2009Publication date: April 21, 2011Inventors: Chin-Tsai FAN, Chen-Ming Hsiao, Rong-Bin Hsieh
-
Publication number: 20110091520Abstract: Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.Type: ApplicationFiled: November 29, 2010Publication date: April 21, 2011Inventors: Glenn T. Huang, Thierry Nivaggioli
-
Publication number: 20110086847Abstract: The present invention relates to new thiadiazole modulators of beta adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 9, 2010Publication date: April 14, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20110082131Abstract: Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed.Type: ApplicationFiled: December 10, 2010Publication date: April 7, 2011Applicant: Rigel Pharmaceuticals, Inc.Inventors: Rajinder Singh, Catherine Sylvain, Sacha Holland, Jing Zhang, John J. Partridge, Jeffrey Clough, Ankush Argade
-
Publication number: 20110077249Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.Type: ApplicationFiled: September 29, 2010Publication date: March 31, 2011Applicant: Janssen Pharmaceutica N.V.Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
-
Publication number: 20110070297Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.Type: ApplicationFiled: December 1, 2010Publication date: March 24, 2011Applicants: Takeda San Diego, Inc., Takeda Pharmaceutical Company LimitedInventors: Sheldon X. Cao, Jun Feng, Yasuhiro Imaeda, Stephen L. Gwaltney, David J. Hosfield, Nobuyuki Takakura, Mingnam Tang
-
Publication number: 20110059936Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: November 9, 2010Publication date: March 10, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, JR., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
-
Publication number: 20110053907Abstract: Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine, and pyridyl-triazine derivatives which are selective irreversible inhibitors of the p110? isoform of PI3K.Type: ApplicationFiled: March 26, 2009Publication date: March 3, 2011Applicant: Auckland UniServices LimitedInventors: Gordon William Rewcastle, Peter Robin Shepherd, Glaire Chaussade, William Alexander Denny, Swarnalatha Akuratiya Gamage
-
Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions
Patent number: 7897603Abstract: The present invention relates to the CGRP-antagonists of general formula I wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.Type: GrantFiled: June 16, 2009Date of Patent: March 1, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Stephan Georg Mueller, Klaus Rudolf, Philipp Lustenberger, Dirk Stenkamp, Marco Santagostino, Fabio Paleari, Henri Doods, Kirsten Arndt, Gerhard Schaenzle -
Publication number: 20110046125Abstract: The present invention relates to compounds for treating or preventing infection that inhibit the activity of Hsp90.Type: ApplicationFiled: October 17, 2007Publication date: February 24, 2011Applicant: SYNTA PHARMACEUTICALS CORP.Inventor: Weiwen Ying
-
Publication number: 20110046120Abstract: The present disclosure provides methods and compositions for treating Impulse Control disorders including, for example, pathological gambling using ?2-adrenergic agonists, ?-adrenergic receptor antagonists, or both.Type: ApplicationFiled: October 25, 2007Publication date: February 24, 2011Inventor: Igor Elman
-
Publication number: 20110046136Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.Type: ApplicationFiled: March 29, 2007Publication date: February 24, 2011Applicant: THERAPEUTICS, INC.Inventors: Neil G. Almstead, Guangming Chen, Hirawat Samit, Peter Seongwoo Hwang, Gary M. Karp, Langdon Miller, Young-Choon Moon, Hongyu Ren, James J. Takasugi, Ellen M. Welch, Richard G. Wilde, Paul Kennedy
-
Publication number: 20110028446Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: ApplicationFiled: October 8, 2010Publication date: February 3, 2011Inventors: Donald J.P. Pinto, Joanne M. Smallheer, James R. Corte, Zilun Hu, Cullen L. Cavallaro, Paul J. Gilligan, Mimi L. Quan, Leon M. Smith, II
-
Publication number: 20110028477Abstract: Disclosed herein are stable formulations suitable for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: November 7, 2008Publication date: February 3, 2011Applicant: TECHNOPHARMA SAInventors: Danilo Aleo, Sergio Mangiafico, Maria Grazia Antonietta Saita
-
Publication number: 20110021489Abstract: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.Type: ApplicationFiled: May 27, 2010Publication date: January 27, 2011Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Dirk HEIMBACH, Susanne Röhrig, Yolanda Cancho Grande, Eckhard Bender, Katja Zimmermann, Anja Buchmüller, Christoph Gerdes, Mark Jean Gnoth, Kersten Matthias Gericke, Mario Jeske
-
Publication number: 20110021526Abstract: A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose reductase, one of the chief causative factors of diabetic complications. Also provided are methods of diabetic wound healing. Compositions for treating diabetic complications, such as diabetic wounds, are disclosed. The present invention includes employing a topical formulation of a beta-blocker, having substantially no antibacterial activity, to improve the process of diabetic wound healing. The present invention also involves increasing the rate of collagen accumulation of the healing epithelialized tissue in the wound of a diabetic individual.Type: ApplicationFiled: January 24, 2008Publication date: January 27, 2011Applicant: VLife Science Technologies Pvt. Ltd.Inventor: Supreet K. Deshpande
-
Patent number: 7875609Abstract: The present invention provides compounds of Formula (I): in which R1, R?1, R2, R?2, R3, and Y have the meanings given in the description are useful in the treatment of conditions susceptible to modulating ion channels, to a process for their preparation, their application by way of medicaments, and to pharmaceutical compositions containing them.Type: GrantFiled: October 31, 2006Date of Patent: January 25, 2011Assignee: Galapagos SasuInventors: Hélène Jary, Taoues Temal, Pierre DePrez
-
Publication number: 20110009397Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.Type: ApplicationFiled: October 23, 2009Publication date: January 13, 2011Inventors: Weiwen Ying, David James, Shijie Zhang, Teresa Przewloka, Junghyun Chae, Dinesh U. Chimmanamada, Chi-Wan Lee, Elena Kostik, Howard P. Ng, Kevin Foley, Zhenjian Du, James Barsoum
-
Publication number: 20110009362Abstract: Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided.Type: ApplicationFiled: February 27, 2009Publication date: January 13, 2011Applicants: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Mahendra Ramachandra Joshi, Nithya Radhakrishnan, Munish Kumar Dhiman, Pradeep Jairao Karatgi, Sanjay Chhagan Wagh, Raviraj Sukumar Pillai, Harshal Prabhakar Bhagwatwar, Venkata Nookaraju Sreedharala
-
Publication number: 20110009409Abstract: In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.Type: ApplicationFiled: July 2, 2010Publication date: January 13, 2011Inventors: Brooke Blair, Paul R. Fatheree, Melissa Fleury, Roland Gendron, Ryan Hudson, Robert Murray McKinnell, Michael Wilson
-
Publication number: 20110009410Abstract: The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).Type: ApplicationFiled: July 12, 2010Publication date: January 13, 2011Applicant: Gilead Sciences, Inc.Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, JR., Gregory Notte
-
Publication number: 20110003806Abstract: This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.Type: ApplicationFiled: January 28, 2010Publication date: January 6, 2011Applicants: Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company LimitedInventors: Masaaki Hirose, Steven P. Langston, Hirotake Mizutani, Stepan Vyskocil
-
Publication number: 20110003816Abstract: An ophthalmic composition comprising therapeutically effective amount of a beta-blocker and a polymeric vehicle consisting essentially of a water soluble cellulose derivative and polyvinylpyrrolidone; wherein the composition is a clear aqueous solution with a viscosity id 20 cps to 60 cps.Type: ApplicationFiled: March 9, 2009Publication date: January 6, 2011Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITEDInventors: Arindam Halder, Ajay Jaysingh Khopade, Subhas Balaram Bowmick
-
Publication number: 20110003807Abstract: The present invention relates to a compound represented by the formula (I) or (I?): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.Type: ApplicationFiled: January 28, 2010Publication date: January 6, 2011Applicants: Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company LimitedInventors: Hiroshi Banno, Masaaki Hirose, Osamu Kurasawa
-
Publication number: 20110003815Abstract: The present invention provides compounds of Formula I which are FLAP inhibitors useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.Type: ApplicationFiled: October 6, 2008Publication date: January 6, 2011Inventors: Anthony Ogawa, Feroze Ujjainwalla, Bing Li, Lin Chu, Minal Patel, Helen M. Armstrong, Hyun O. Ok, Rosemary Sisco, Dwight MacDonald, John Hutchinson, Helene Perrier
-
Publication number: 20100331302Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: July 8, 2010Publication date: December 30, 2010Applicant: Chemocentryx, Inc.Inventors: Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Edward J. Sullivan, William D. Thomas, Solomon Ungashe, Penglie Zhang, Jay Powers, Sreenivas Punna
-
Publication number: 20100330146Abstract: An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator.Type: ApplicationFiled: July 22, 2010Publication date: December 30, 2010Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: ANUJ CHAUHAN, JINAH KIM
-
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
Patent number: 7858622Abstract: The present invention relates to the CGRP antagonists of general formula I wherein R1, R2, R3 and R4 are as defined in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.Type: GrantFiled: June 17, 2009Date of Patent: December 28, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Stephan Georg Mueller, Klaus Rudolf, Philipp Lustenberger, Gerhard Schaenzle, Marco Santagostino, Dirk Stenkamp, Kirsten Arndt, Henri Doods -
Publication number: 20100317653Abstract: Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.Type: ApplicationFiled: August 3, 2010Publication date: December 16, 2010Applicant: AstraZeneca ABInventors: Alan Martin BIRCH, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William Mccoull, Thorsten Nowak, Alleyn Plowright
-
Publication number: 20100316678Abstract: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology.Type: ApplicationFiled: June 26, 2008Publication date: December 16, 2010Applicant: CNSBio Pty Ltd.Inventor: Colin Stanley Goodchild
-
Publication number: 20100317652Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y? are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.Type: ApplicationFiled: May 11, 2010Publication date: December 16, 2010Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Lee Richard Roberts, Thomas Ryckmans
-
Publication number: 20100317664Abstract: Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereofType: ApplicationFiled: April 5, 2010Publication date: December 16, 2010Inventors: Qingyun Liu, Brian Zambrowicz
-
Publication number: 20100310622Abstract: A punctal plug and method of treating dry eyes are provided. The punctal plug has two or three layer structure and contains at least one drug, for treating conditions such as dry eyes contained in a core, a potion of which is covered by a drug impermeable shell such that drug can radially diffuse from the core. The punctal plug can be inserted into a patient's upper punctum, lower punctum, or both to deliver the drug for an extended period of time. The drug for treating dry eyes can be, for example, cyclosporine A. The plug can also be used for extended delivery of ophthalmic drugs.Type: ApplicationFiled: December 17, 2008Publication date: December 9, 2010Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Anuj Chauhan, Heng Zhu
-
Publication number: 20100311705Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: ApplicationFiled: May 5, 2010Publication date: December 9, 2010Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20100305104Abstract: The invention relates to compounds of formula (I): wherein R1, R2, Ra, Rb, Rc and W, have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.Type: ApplicationFiled: October 1, 2008Publication date: December 2, 2010Inventors: Cyril Montagne, Anna Quattropani, Wolfgang Sauer, Agnes Bombrun
-
Publication number: 20100305092Abstract: The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, X have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.Type: ApplicationFiled: December 17, 2008Publication date: December 2, 2010Applicant: MERCK SERONO SAInventors: Anna Quattropani, Christophe Cleva, Eric Sebille, Matthias Schwarz, Delphine Marin
-
Publication number: 20100305085Abstract: The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.Type: ApplicationFiled: October 12, 2007Publication date: December 2, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
-
Publication number: 20100298312Abstract: The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.Type: ApplicationFiled: September 3, 2008Publication date: November 25, 2010Applicant: The Scripps Research InstituteInventors: Theodore M. Kamenecka, Rong Jiang, Xinyi Song, Philip LoGrasso, Michael D. Cameron, Derek R. Duckett
-
Publication number: 20100298327Abstract: Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific Hweight ratios of the forms.Type: ApplicationFiled: March 29, 2007Publication date: November 25, 2010Applicants: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Vijayavitthal Thippannachar Mathad, Pravinchandra Jayantilal Vankawala, Raviram Chandrasekhar Elati, Prabhakar Macharla, Srinivas Gangula, Naveen Kumar Kolla, Ravi Kumar Komareddy, Surya Narayana Devarkonda, Subbareddy Peddireddy
-
Publication number: 20100297097Abstract: The present invention relates to substituted triazole compounds of the formula (I): and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and the treatment of symptoms linked to the production of the amyloid plaque-forming A?42 peptide such as Alzheimer's disease and the like.Type: ApplicationFiled: November 7, 2008Publication date: November 25, 2010Inventors: Anne Marie Jeanne Bouillot, Alain Laroze
-
Publication number: 20100286149Abstract: This invention relates to novel benzamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels.Type: ApplicationFiled: November 25, 2008Publication date: November 11, 2010Inventors: Antonio Nardi, Jeppe Kejser Christensen
-
Publication number: 20100286148Abstract: A pyridine compound represented by the following general formula (1); the pyridine compound in which R1 is a C1-C3 fluoroalkyl group or a C1-C3 fluoroalkoxy group; the pyridine compound in which R2 is a hydrogen atom; the pyridine compound in which R2 is a group represented by Q; a pesticidal composition containing the pyridine compound as an active ingredient; and a method of controlling a pest including applying an effective amount of the pyridine compound to the pest or a place where the pest inhabits, are provided.Type: ApplicationFiled: November 18, 2008Publication date: November 11, 2010Inventor: Hajime Mizuno
-
Publication number: 20100280003Abstract: The invention provides a pharmaceutical combination comprising: a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and b) at least one JAK kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.Type: ApplicationFiled: July 12, 2010Publication date: November 4, 2010Inventors: Nigel Graham Cooke, Paul W. Manley
-
Publication number: 20100280032Abstract: The present invention relates to a method for suppressing the immune system in a subject in need thereof, and a method for treating an inflammatory or immune disorder in a subject in need thereof.Type: ApplicationFiled: October 25, 2007Publication date: November 4, 2010Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Dan Zhou, Shuzhen Qin, Weiwen Ying
-
Publication number: 20100273764Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.Type: ApplicationFiled: April 27, 2010Publication date: October 28, 2010Applicant: Amgen Inc.Inventors: Kristin Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L.M. Jackson, Brian A. Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin Yang
-
Publication number: 20100267725Abstract: The present invention relates to compounds, compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or 2 or encompassed by formula I) or compositions comprising these compounds, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.Type: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Inventors: Michael Geoffrey Neil Russell, Kevin James Doyle
-
Publication number: 20100266714Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: ApplicationFiled: October 29, 2008Publication date: October 21, 2010Inventors: Christopher S Burgey, Diem Nguyen, Zhengwu Deng, Daniel V. Paone, Craig M. Potteiger, Joseph P. Vacca